NCT06057922 2026-03-12
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Active not recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
M.D. Anderson Cancer Center
Chinese PLA General Hospital
Jiangsu HengRui Medicine Co., Ltd.
Instituto Oncológico Dr Rosell